Hemodynamic effects of nifedipine in acute myocardial infarction with observations on infarct size.
To assess the safety of the slow calcium-channel blocker nifedipine in patients with acutely evolving myocardial infarction, hemodynamic effects of the drug were studied in 12 patients and infarct size was determined by enzymatic method in 14 patients presenting within 12 h of onset of pain. Nifedipine (3 doses of 20 mg given sublingually at 8-h intervals) produced a significant increase in heart rate and cardiac output accompanied by a fall in systemic arterial pressure and vascular resistance. These effects were sustained for a 24-h period of study. Despite an increase in heart rate and cardiac output, there was no worsening of symptoms or electrocardiographic evidence of myocardial ischemia. Assessment of infarct size did not reveal any differences between the control group and the patients who received nifedipine. We conclude that nifedipine may be safely given to patients with acute myocardial infarction. The drug may be usefully employed in patients with acute myocardial infarction accompanied by angina or hypertension.
P A
PA
Majid
J
J
Niznick
S
S
Nishizaki
A
A
Haq
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D009543:Nifedipine / Q000627:therapeutic use*; D013997:Time Factors
D007527:Isoenzymes; D003402:Creatine Kinase; D009543:Nifedipine